HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 22, No 11, November 2018 – The Asian Cancer - War on liver cancer       » 2018 Nobel Prize in Physiology or Medicine winners       » Women more prone to selected chemotherapy side effects       » Tibetan fungus could help fight liver cancer       » Standards for TCM decoction to be applied globally       » RMB200 million donation to build Tsinghua University Biomedical Sciences Building      
INSIDE INDUSTRY
China, Brazil and Russia named by healthcare companies as riskiest markets for compliance and regulation
Healthcare companies cite regulation and compliance as their biggest headache, followed by intellectual property threats. The UK and US were also identified as markets that pose significant risk.

Healthcare and life science companies have named China, Brazil and Russia as the three riskiest markets to do business in, according to new research from global law firm Ropes & Gray.

The research - based on a global survey of 300 senior-level executives working for multi-national businesses in North America, EMEA, Asia Pacific and Latin America, in the healthcare, life sciences, asset management, banking, private equity and technology sectors – revealed that 22% of healthcare and life science companies cited China and a further 16% cited both Brazil and Russia as markets that pose the ‘most significant risk’ to their businesses. The UK and US were identified (by 10% of companies in both cases) as the next most risky markets to operate in.

By way of comparison, just 4% of healthcare and life sciences companies named India and Mexico, 2% named Germany, Italy and Japan, and none named Canada, France or Indonesia.

Mimi Yang, co-head of the Ropes & Gray Global Healthcare Compliance team said, “It is no surprise that China, Brazil, and Russia are viewed by healthcare and life sciences companies as the riskiest markets. These markets are often where economic growth is highest. However, in order to achieve that growth, companies doing business in those markets must also compete for market share in an industry where compliance and transparency are less mature than their more developed counterparts, and where enforcement of domestic regulations can be somewhat arbitrary.”

Amanda Raad, international risk partner at Ropes & Gray and a co-head of the firm’s Global Healthcare Compliance team added, “The UK and US are prominent because of the extensive extra-territorial legislation and enforcement reaching other high risk markets. China, Brazil and Russia are prime examples of countries targeted by corruption and sanctions laws in the US and UK.”

Most multi-national companies (57%) listed ‘regulation and compliance’ as the top type of risk they’re least prepared to address, with 78% saying they intend to devote the most risk management resources to deal with regulation and compliance risks in the future.

Again, these figures were even higher among healthcare and life science companies, with 62% admitting they were least prepared to address regulation and compliance risks, and 72% saying they planned to devote more resources in this area going forward.

Intellectual property issues were identified as the second biggest area of concern by companies in the pharma sector, with over a quarter (26%) - compared with just 11% of all multi-nationals - admitting they are unprepared to deal with threats in this area. Just under a quarter (24% in both cases) also felt unprepared to deal with anti-money laundering and sanctions risks. In response 18% of life science companies indicated they would increase resources to deal with all these issues over the next 12 months.

Alison Fethke, co-head of the Ropes & Gray Global Healthcare Compliance team said: “Historically, companies in the pharmaceutical and medical device sector have viewed their US regulatory and legal risks, including the FCPA, as far more substantial than those outside of the US However, over recent years, this framework has begun to change, and these companies are now contending with increasing enforcement and potential legal liability relating to corruption, money laundering, anti-trust, intellectual property, cybersecurity, data privacy and tax on a global scale.”

Amanda Raad added: “At the same time, because the regulatory focus has slowly evolved over time, many companies have tried to address each risk on an individual basis, rather than taking a co-ordinated, centralised approach. This is leaving many companies now struggling to effectively prioritise and efficiently tackle the breadth of risks they face.”

Source: Ropes & Gray

Click here for the complete issue.

NEWS CRUNCH  
news Asia is the fastest growing region for nutraceuticals
news 2018 Nobel Prize in Physiology or Medicine winners
news Vitafoods Asia expands by 40 per cent in 2018
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  

APBN Editorial Calendar 2018
January:
Obesity / Outlook for 2018
February:
Searching for the fountain of youth
March:
Women in Science - Making a difference
April:
Digestive health in the 21st century - Trust your guts
May:
Dental health - The root to good health
June:
Cancer - Therapies and strategies for better patient outcomes
July:
Water management - Technologies for biotech and pharmaceutical industries
August:
Regenerative technology - Meat of the future
September:
Doctor Robot - The digital healthcare revolution
October:
Bones / Breast cancer
November:
Liver health / Top science research nations & institutions
December:
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy